Efficient help for autoreactive B‐cell activation requires CD4⁺ T‐cell recognition of an agonist peptide at the effector stage

Abstract

T-cell recognition of peptide/MHC complexes is flexible and can lead to differential activation, but how interactions with agonist (full activation) or partial agonist (suboptimal activation) peptides can shape immune responses in vivo is not well characterized. We investigated the effect of stimulation by agonist or partial agonist ligands during initial CD4 1 T-cell priming, and subsequent T-B-cell cognate interactions, on antibody production by anti-chromatin B cells. We found that autoantibody production required TCR recognition of an agonist peptide at the effector stage of B-cell activation. However, interaction with a weak agonist ligand at this effector stage failed to promote efficient autoantibody production, even if the CD4 1 T cells were fully primed by an agonist peptide. These studies suggest that the reactivity of the TCR for a target self-peptide during CD4 1 T-B-cell interaction can be a critical determinant in restraining anti-chromatin autoantibody production.

ICOS expression by effector T cells influences the ability of regulatory T cells to inhibit anti-chromatin B cell responses in recipient mice

“…Spleens were frozen, sectioned, and stained [22] with anti-B220-biotin (RA3-6B2) (BD Pharmingen) and PNA-FITC (Sigma). Secondary reagents were anti-FITC-horseradish peroxidase (HRP) and streptavidin-AP (Southern Biotechnologies).…”